Amendments To The Claims

The listing of claims presented below will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (previously presented) A compound which is 5'-lauric acid ester of riboflavin.

2- 5 (canceled)

6. (previously presented) An oil suspension preparation comprising as a main active constituent being mainly composed of ethyl oleate and the compound of Formula II:



Formula II.

7. (previously presented) The suspension preparation according to claim 6, wherein camellia oil is added and the ratio of weight and volume of each ingredient are as follows:

Compound of Formula II	50 - 150 mg,
Ethyl oleate	0.1 - 1 ml, and
Camellia oil	0-1 ml.

8. (previously presented) The suspension preparation according to claim 7, wherein

the preferable ratio of weight and volume of each ingredient are as follows:

Compound of Formula II	150 mg,
Ethyl oleate	0.5 ml, and
Camellia oil	0.5 ml.

9-11. (canceled)

12. (previously presented) A method of therapeutically treating either an ariboflavinosis condition, a digestive tract catarrh, or a persistent oral ulcer of an animal comprising the steps of:

obtaining a suspension preparation containing a main active constituent being mainly composed of ethyl oleate and the compound of Formula II:



Formula II; and

administering a portion of the suspension preparation to the animal.

13-20. (canceled)

21. (previously presented) The method of claim 12 further comprising the step of: subjecting the animal to a chemotherapy regimen.

22. (currently amended) The method of claim 21 wherein the chemotherapy regimen is

selected from the group consisting of high-dose methotrexate (HDMTX) chemotherapy, and DA (daunorubicin) and CODPL ~~daunorubicin, cytosine arabinoside)~~ chemotherapy.

~~22~~23. (currently amended) The method of claim 12 wherein the administering step comprises injecting the portion of the suspension preparation into the animal.

~~23~~24. (currently amended) The method of claim 12 wherein the administering step comprises injecting intermuscularly the portion of the suspension preparation into the animal.

~~24~~25. (currently amended) The method of claim 12 wherein the administering step comprises feeding the portion of the suspension preparation to the animal.

~~25~~26. (currently amended) The method of claim 12, wherein the suspension preparation is used to treat the ariboflavinosis condition.

~~26~~27. (currently amended) The method of claim 12, wherein the suspension preparation is used to treat digestive tract catarrh caused by bone marrow transplantation, leukemia or chemotherapy.

~~27~~28. (currently amended) The method of claim 12, wherein the suspension preparation is used to treat persistent oral ulcer.

~~28~~29. (currently amended) The method of claim 12, wherein the animal is a rat.

~~29~~30. (currently amended) The method of claim 12, wherein the animal is a human.

~~30~~31. (currently amended) The method of claim 12, wherein the suspension preparation further contains camellia oil.

~~31~~32. (currently amended) The method of claim 29, wherein the suspension preparation is combined with relative ranges of weights and volumes of each ingredient as follows:

Compound of Formula II	50 - 150 mg;
Ethyl oleate	0.1 - 1 ml; and
Camellia oil	0-1 ml.

~~32~~33. (currently amended) The method of using the compound of claim 31, wherein the suspension preparation is combined with relative ranges of weights and volumes of each ingredient as follows:

Compound of Formula II	150 mg,
Ethyl oleate	0.5 ml, and
Camellia oil	0.5 ml.

34. (new) A compound which is 5'-lauric acid ester of riboflavin for intramuscular injection.